GlassScriptPhysician profile
Barbara M Wysocki
NPI 1588041156
$5,907.25
in general payments reported to CMS, 2019-2025
40 companies · $612 in 2025
The $612 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,268 · 2022: $1,692 · 2023: $1,329 · 2024: $1,005 · 2025: $612.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,947.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,946.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,091.59 | 2021-2025 | |
| Boston Scientific Corporation | $443.26 | 2021-2025 | Lux-Dx Insertable Cardiac Monitor, General - Therapies, Lithovue Empower |
| Impulse Dynamics (USA) INC. | $386.09 | 2021-2024 | Optimizer, Optimizer |
| Actelion Pharmaceuticals US, INC. | $377.28 | 2022-2024 | Opsumit, Uptravi |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $296.40 | 2021-2025 | Lifevest |
| Edwards Lifesciences Corporation | $289.05 | 2021-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Atricure, INC. | $281.87 | 2023-2024 | |
| Novo Nordisk INC | $262.60 | 2021-2025 | Wegovy, Ozempic |
| Amarin Pharma, INC. | $222.41 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $220.11 | 2021-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $210.97 | 2021-2023 | Verquvo |
| Nuwellis, INC. | $170.04 | 2022 | |
| Abbott Laboratories | $169.44 | 2022 | |
| Kestra Medical Technology Services, INC. | $154.14 | 2022-2024 | Assure Wcd |
| Daiichi Sankyo INC. | $146.16 | 2022-2023 | Injectafer |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $123.01 | 2021-2024 | Repatha |
| Astrazeneca Pharmaceuticals LP | $108.55 | 2021-2025 | Farxiga |
| Esperion Therapeutics, INC. | $106.40 | 2021-2025 | Nexletol |
| Chiesi USA, INC. | $101.78 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.36 | 2021-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $86.00 | 2021-2025 | Eliquis |
| Kiniksa Pharmaceuticals International, Plc | $69.22 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $60.36 | 2021-2023 | Arcalyst |
| Acacia Pharma INC | $52.71 | 2021-2022 | |
| Cmp Pharma, INC. | $48.08 | 2023-2025 | Atorvaliq, Norliqva, Carospir |
| Alnylam Pharmaceuticals INC. | $38.70 | 2021-2022 | |
| Tactile Systems Technology INC | $36.84 | 2024 | Flexitouch Plus, Entre Plus |
| Biotronik INC. | $35.98 | 2021 | |
| Amryt Pharma Holdings LTD | $27.06 | 2023 | Juxtapid |
| Pfizer INC. | $25.53 | 2022 | |
| Angiodynamics, INC. | $21.63 | 2025 | Auryon Laser System 100-120 Vac |
| Astellas Pharma US INC | $21.05 | 2021 | |
| Lundbeck LLC | $20.06 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.99 | 2025 | |
| Medtronic, INC. | $17.42 | 2023 | Endurant Iis |
| Lexicon Pharmaceuticals, INC. | $15.72 | 2024 | |
| Scpharmaceuticals INC. | $15.60 | 2023 | |
| Sanofi-Aventis U.S. LLC | $15.35 | 2024 | |
| Kci USA, INC. | $14.90 | 2023 | Prevena, V.A.C.Ulta |
| Vivaquant INC, Dba Rhythm Express | $6.54 | 2025 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Wysocki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.